November 17, 2016 5:13pm
… The theme of the week was the skirmish of oversold and overbought as “power perceived is power achieved” in relation to share pricing and value
After a negative open, a positive close ensued – right again!
I answer one question; in which company should investors put, keep and commit their money!
Pre-open indication’s tally: 4 hits (AGTC, BLCM, HSGX and STEM) and 1 miss (AST)
Lose an advantage or be a subscriber! Today’s results have implications to Friday's sector activity.
I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
There are two things that investors need - interpretation of news and translation of market metrics concerning the stem, cell, gene and regenerative therapy sector to substantiate share pricing.
U.S. equities rose on Thursday, putting the major indexes close to all-time highs, as investors parsed through economic data and Federal Reserve Chair Janet Yellen's testimony.
The NASDAQ closed UP +39.39 or +0.74% to 5,333.97 and the DOW closed UP +35.68 or +0.19% to 18,903.82.
A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:
- The open was negative with an A/DL of 16/22 and 5 flats;
- The mid-day flipped positive with an A/DL of 25/16 and 2 flats;
- The closing bell was positive with A/DL of 28/15 and 0 flat;
Henry’omics:
The stem, cell, gene and regenerative therapy (SCG&RT) sector opened negative, turned positive at the mid-day and closed positive.
- From this morning’s investor’s letter, “The dice are being shaken. If the “come out” roll is a 7 or 11, these results in a win for pass line bets –it’s time for some sector equities” – it was a statement that meant, the sector would end … positive today.”
And it did end … UP after two down days … but, I still adhere to the premise of DIALING back expectation until the end of the year!!
- The question will be … the resistance zones on Friday?
At the close …
- Gainers included Asterias Biotherapeutics (NYSEMKT: AST +0.60), ReNeuron (RENE.L +$0.25), Cesca Therapeutics (KOOL +$0.24) and Capricor (CAPR +$0.14) contributed the most gains;
- The biggest losers of the session were StemCells (STEM -$0.30), Cellectis SA (CLLS -$1.39), Opexa (OPXA -$0.04) and Spark therapeutics (ONCE -$3.39)…
The CBOE Volatility Index (VIX), widely considered the best gauge of fear in the market, traded lower, near 13.5.
The iShares Russell 2000 (IWM) indicated a positive pre- open of +0.32% and closed UP +0.59% while the iShares NASDAQ Biotechnology (IBB) indicate a pre-open negative of -0.15% and closed UP +0.70%.
The downside trend reflects a pricing trend range of:
- Thursday’s decliners ranged from -0.78% <JUNO> to-21.28% <STEM> in 15 equities;
- Wednesday’s decliners ranged from -0.42% <STML> to -14.93% <IMUC> in 26 equities;
- Tuesday’s decliners ranged from -0.02% <OPXA> to -9.52% <RENE.L> in 27 equities;
- Monday’s decliners ranged from –o.21% <CLLS> to -6.48% <FATE> in 17 equities;
- Friday’s decliners ranged from -0.61% <CYTX> to -10.79% <IMUC> in 10 equities;
- Last Thursday’s decliners ranged from -0.03% <CAPR> to -8.61% <HSGX> in 11 equities;
The upside shows a pricing trend range of:
- Thursday’s gainers ranged from +0.14% <IMUC> to +12.50% in 28 equities;
- Wednesday’s gainers ranged from +0.46% <OSIR> to +31.78% <STEM> to in 13 equities;
- Tuesday’s gainers ranged from +0.58% <AXGN> to +11.11% <CLBS> in 13 equities
- Monday’s gainers ranged from +0.59% <ATHX> to +15.62% <CAPR> <> in 23 equities;
- Friday’s gainers ranged from +0.53% <VTGN> to +36.28% <FATE>in 31 equities;
- Last Thursday’s advancer’s ranged from +0.61% <AXGN> to +46.91% in 30 equities;
Wrap-up: anybody can read a paragraph … review the percentage changes per day in the week of the decliners and advancers. The shifting correlation of the number of equites inclining versus the decliners hasn’t abated!
- Thursday’s 28 gainers followed Wednesday’s 13 post Tuesday’s 13 followed Monday’s 23 after Friday’s 31 compared to last Thursday’s 30 …
- Thursday’s 15 decliners followed Wednesday’s 26 after Tuesday’s 27 decliners post Monday’s 17 compared to Friday’s 10 after last Thursday’s 11...
Pre-open indication’s tally: 4 hits (AGTC, BLCM, HSGX and STEM) and 1 miss (AST)
- Applied Genetics Technologies (AGTC) closed UP +$0.25 – hit;
- Asterias Biotherapeutics (NYSEMKT: AST) closed UP +$0.60 – miss;
- Bellicum Pharma (BLCM) closed UP +$0.36 – hit;
- Histogenics (HSGX) closed UP +$0.07 – hit;
- StemCells (STEM) closed DOWN -$0.30 – hit;
Percentage decliners:
- StemCells (STEM) -21.28% after Wednesday’s +31.78%;
- Cellectis SA (CLLS) -7.06% after Wednesday’s +5.12%;
- Opexa (OPXA) -6.76% after Wednesday’s +5.34%;
- Spark Therapeutics (ONCE) -5.53%
- Fate therapeutics (FATE) -4.91%
Percentage advancers:
- Asterias Biosciences (NYSEMKT: AST) +12.50% after Wednesday’s +9.09%;
- ReNeuron (RENE.L) +10.53%;
- Cesca Therapeutics (KOOL) +7.62%;
- Capricor (CAPR) +4.75%;
- Mesoblast (MESO) +4.39%
Flat:
- 0
Review my fear gauge or the CBOE Volatility Index (VIX):
· Thursday traded near 13.5;
· Wednesday traded near 13.9;
· Tuesday traded near 13.4;
· Monday traded near 14.9;
· Friday traded near 14.17 – a 3.87% decrease;
· Last Thursday traded near 14.74;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
